Earnings summaries and quarterly performance for Serina Therapeutics.
Executive leadership at Serina Therapeutics.
Board of directors at Serina Therapeutics.
Research analysts covering Serina Therapeutics.
Recent press releases and 8-K filings for SER.
Serina Therapeutics Reports Q3 2025 Financial Results and SER-252 Clinical Hold
SER
Earnings
New Projects/Investments
Debt Issuance
- Serina Therapeutics reported a net loss attributable to Serina of $4.6 million, or $(0.45) per basic and diluted share, for the third quarter ended September 30, 2025.
- As of September 30, 2025, the company had $8.6 million in cash and cash equivalents.
- The FDA placed the Investigational New Drug (IND) for SER-252 on clinical hold on November 3, 2025, pending additional information regarding a commonly used formulation excipient, despite prior FDA alignment on a 505(b)(2) NDA pathway.
- In September 2025, Serina secured a convertible note and warrant financing agreement providing up to $20 million in funding, with the first $5 million tranche drawn. Additionally, the company generated net proceeds of $2.8 million from its At-the-Market (ATM) equity program as of November 7, 2025.
Nov 13, 2025, 11:05 AM
Serina Therapeutics draws first $5 million funding tranche for SER-252 trial
SER
Debt Issuance
New Projects/Investments
- Serina Therapeutics, Inc. (SER) has drawn the first $5 million tranche of funding from a previously announced financing agreement, which provides up to $20 million.
- These proceeds will be used to advance the planned registrational trial of SER-252 for the treatment of advanced Parkinson's disease.
- The company has submitted an Investigational New Drug (IND) application to the FDA and received Human Research Ethics Committee (HREC) approval in Australia, remaining on track to initiate the study in Q4 2025.
Oct 6, 2025, 8:12 PM
Serina Therapeutics, Inc. enters into $20 million convertible note agreement
SER
Debt Issuance
New Projects/Investments
- Serina Therapeutics, Inc. entered into a senior unsecured convertible promissory note with Gregory H. Bailey, M.D. on September 9, 2025, making available up to $20 million in principal amount.
- The funding is structured in five tranches, contingent upon the achievement of specific clinical and operational milestones related to the company's SER-252-1b registrational clinical study.
- The note bears an annual interest rate of 10% and has a maturity date of five years after the initial funding date, which is September 9, 2030.
- The convertible note is convertible into common stock at $5.18 per share, and accompanying warrants have an exercise price of $5.44 per share.
- The issuance of shares from the note and warrants is limited to 19.99% of outstanding common stock without prior shareholder approval.
Sep 15, 2025, 8:01 PM
Serina Therapeutics Reports Q2 2025 Financial Results and Business Highlights
SER
Earnings
New Projects/Investments
Board Change
- Serina Therapeutics reported a net loss of $6.4 million for the second quarter ended June 30, 2025, or $(0.66) per basic and diluted share, compared to a net income of $5.2 million, or $0.61 per basic share, for the same period in 2024. Revenues for Q2 2025 were $130 thousand, primarily from grant revenues.
- As of June 30, 2025, Serina had $6.0 million in cash and cash equivalents, which are projected to fund operations into the fourth quarter of 2025.
- The company secured $5 million in funding in April 2025 to support the continued development of SER-252, its lead clinical candidate for advanced Parkinson's disease, which is on track to initiate a Phase 1 clinical trial in the fourth quarter of 2025. Additionally, SER-270 for tardive dyskinesia advanced in July 2025.
- Serina also raised $1.2 million in net proceeds from an "at-the-market" (ATM) offering as of August 8, 2025, under an agreement that allows for the sale of up to $13.3 million of common stock. In May 2025, Stephen (Steve) Brannan, M.D., was appointed to the Board of Directors.
Aug 11, 2025, 12:00 AM
Serina Therapeutics Advances POZ-VMAT2i into Development
SER
New Projects/Investments
- Serina Therapeutics, Inc. (SER) announced the advancement of its novel product candidate, SER-270 (POZ-VMAT2i), into development for the treatment of tardive dyskinesia (TD).
- SER-270 is a once-weekly injectable leveraging the company's proprietary POZ Platform™, designed to address significant unmet needs in the U.S. TD market, which exceeded $3.7 billion in sales in 2024 and is projected to grow to $5.4 billion by 2030.
- The company anticipates a potential peak sales opportunity of >$1.1 billion for POZ-VMAT2i and plans to explore its development for Huntington’s chorea.
- Key upcoming milestones include FDA allowance for the Phase 1b trial of SER-252 in Advanced Parkinson’s in August 2025, IND submission in September 2025, and initiation of the Phase 1b trial in November 2025. Target IND-enabling studies for SER-270 are set for Q4 2025.
Jul 29, 2025, 12:00 AM
Serina Therapeutics reports Q1 2025 results
SER
Earnings
New Projects/Investments
Board Change
- Net loss of $4.8 million (−$0.49 per share) in Q1 2025 versus $15.0 million (−$5.38 per share) in Q1 2024, on operating expenses of $5.9 million.
- Cash and cash equivalents of $4.3 million at March 31, 2025, with an additional $5 million received in April, providing runway through Q3 2025.
- $15 million in equity financing secured since late 2024, including a $10 million investment from JuvVentures and a $5 million private placement in April 2025.
- Phase 1b trial of SER-252 for advanced Parkinson’s disease on track for first patient dosing in Q4 2025.
- Board strengthened with the addition of Karen J. Wilson and Dr. Jay Venkatesan during Q1 2025.
May 8, 2025, 12:00 AM
Serina Therapeutics launches ATM equity program and updates capital structure
SER
Convertible Preferred Issuance
- On April 25, 2025, Serina Therapeutics entered into a Capital on Demand™ Sales Agreement with JonesTrading, enabling an “at-the-market” offering of up to $13.27 million of its common stock under its effective Form S-3 registration.
- The Company will pay commissions of up to 3% of gross proceeds and reimburse JonesTrading’s legal fees up to $50,000 in connection with the ATM program.
- On April 8, 2025, Serina issued 962,250 shares of Series A Convertible Preferred Stock at $5.18 per share in a private placement.
- Serina’s authorized capital includes 40 million common shares and 5 million preferred shares, with its board authorized to issue preferred stock without further stockholder approval.
- The updated description of capital stock in Exhibit 4.1 supersedes any prior descriptions in the Company’s SEC filings.
Apr 29, 2025, 12:00 AM
Serina Therapeutics reports Full-Year 2024 results and business highlights
SER
Earnings
New Projects/Investments
- Serina reported $56 thousand in 2024 revenues versus $3.2 million in 2023 and recorded a net loss of $11.1 million (–$1.51/share) compared to 2023 net income of $5.3 million ($2.36/share).
- Cash and equivalents were $3.7 million as of December 31, 2024, with a projected runway through Q2 2025.
- In November 2024 and January 2025, Serina secured $10 million in equity financing from JuvVentures and in December 2024 sold its UniverXome subsidiary, eliminating $11.2 million of debt.
- The company added Karen J. Wilson and Dr. Jay Venkatesan to its board and advanced its partnership with Enable Injections toward a Phase 1b trial of SER-252 in late 2025.
Mar 24, 2025, 12:00 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more